Modified FOLFIRINOX in pancreatic cancer patients Age 75 or older
Jonathan D. Mizrahi, Jane E. Rogers, Kenneth R. Hess, Robert A. Wolff, Gauri R. Varadhachary, Milind Javle, Rachna T. Shroff, Linus Ho, David R. Fogelman, Kanwal Raghav, Michael J. Overman, Shubham Pant
Topics & Concepts
MedicineFOLFIRINOXOxaliplatinIrinotecanToxicityInternal medicineGastroenterologyPancreatic cancerPopulationSurgeryCancerColorectal cancerEnvironmental healthPancreatic and Hepatic Oncology ResearchRenal cell carcinoma treatmentNeuroendocrine Tumor Research Advances